Compare JOB & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOB | LTRN |
|---|---|---|
| Founded | 1893 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 22.2M |
| IPO Year | 2021 | 2020 |
| Metric | JOB | LTRN |
|---|---|---|
| Price | $0.25 | $3.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 249.5K | ★ 282.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,504,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $1.11 |
| 52 Week High | $0.28 | $5.74 |
| Indicator | JOB | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 70.09 |
| Support Level | $0.19 | $3.04 |
| Resistance Level | $0.27 | $3.79 |
| Average True Range (ATR) | 0.01 | 0.30 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 36.64 | 88.72 |
GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.